Talk:Precision BioSciences
This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||||||||||
|
The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.
|
Disclosing COI
[edit]Hello! OJDrucker and I, the authors of the initial draft of this page, have a COI: we've been paid by Precision BioSciences to create this draft. I'm happy to help with any feedback about how to ensure this article is neutral and has encyclopedic value. I want to ensure I am transparent throughout the process of getting this article reviewed for a move to mainspace. Many thanks. Mary Gaulke (talk) 16:45, 24 August 2022 (UTC)
<Precision BioSciences is developing three promising allogeneic CAR T cell therapies for blood cancers:
PBCAR0191: This is their lead candidate targeting CD19, designed to treat non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL). It has received orphan drug and fast track designations from the FDA. In clinical trials, PBCAR0191 has shown encouraging results, with a 100% response rate, 73% complete response rate, and 50% durable response rate in some patient groups12. The therapy has demonstrated an acceptable safety profile with no severe side effects like graft-versus-host disease or high-grade cytokine release syndrome3.
PBCAR19B: This is an advanced "stealth cell" version targeting CD19. It uses a single gene edit to reduce rejection by the patient's immune system. A Phase 1 study for this therapy began in June 20214.
PBCAR269A: This therapy targets B-cell maturation antigen (BCMA) for the treatment of multiple myeloma. It's currently in Phase 1/2a clinical trials, being tested alone and in combination with nirogacestat, a gamma secretase inhibitor56. The FDA has granted it fast track and orphan drug designations.
All three therapies utilize Precision's ARCUS gene editing platform to create "off-the-shelf" CAR T cells, potentially offering more accessible and timely treatment options for patients with these aggressive blood cancers.>
Wiki Education assignment: Engineering in the 21st Century - Section 003
[edit]This article was the subject of a Wiki Education Foundation-supported course assignment, between 19 August 2024 and 3 December 2024. Further details are available on the course page. Peer reviewers: 4evayyxy.
— Assignment last updated by 4evayyxy (talk) 01:59, 14 November 2024 (UTC)
- Start-Class AfC articles
- AfC submissions by date/29 December 2022
- Accepted AfC submissions
- Start-Class company articles
- Unknown-importance company articles
- WikiProject Companies articles
- Start-Class pharmacology articles
- Unknown-importance pharmacology articles
- WikiProject Pharmacology articles
- Talk pages of subject pages with paid contributions